The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.

Background and objective Inhibitors of mesenchymal-epithelial transition (MET) receptor serve as significant therapeutic agents in MET-driven non-small cell lung cancer (NSCLC). Among these, capmatinib has demonstrated particularly notable efficacy and safety. However, the mechanisms responsible for... View More